CGEM- Cullinan Therapeutics, Inc.

Name: Cullinan Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Cullinan Therapeutics, Inc. (CGEM) has 13 insiders with recent SEC Form 4 filings, including 0 buys and 34 sells. CGEM is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
10%	Lynx1 Capital Management LP	8.96M	$146.37M	-
CEO	Ahmed Nadim	420.7K	$6.87M	-
Other	Jones Jeffrey Alan	169.5K	$2.77M	-
Other	Sumer Jacquelyn L	135.4K	$2.21M	-
Other	Michaelson Jennifer	132.6K	$2.17M	-

Activity

Buys and sells only

Transactions

10 filings · page 10

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Sep 8, 2021	Trigilio Jeffrey51	Chief Financial Officer	Sale+OE	15,000	$28.48	$427,153.26	-51.7%	-39.6%	-52.5%
Sep 8, 2021	Baeuerle Patrick	See Remarks	Sale+OE	11,000	$28.45	$312,950.00	-100%	-39.6%	-52.5%
Sep 8, 2021	Ubs Oncology Impact Fund L.P.89	10% Owner	Sell	48,640	$29.20	$1,420,393.90	-0.2%	-39.6%	-52.5%
Sep 8, 2021	Gadicke Ansbert85	Director, 10% Owner	Sell	55,364	$29.20	$1,616,749.39	-0.2%	-39.6%	-52.5%
Sep 7, 2021	Zawel Leigh82	See Remarks	Sell	28,118	$28.95	$814,016.10	-30.1%	-41.8%	-53.9%
Sep 2, 2021	Gadicke Ansbert85	Director, 10% Owner	Sell	27,669	$29.50	$816,352.16	-	-44.2%	-55.5%
Sep 2, 2021	Ubs Oncology Impact Fund L.P.89	10% Owner	Sell	24,309	$29.50	$717,217.77	-	-44.2%	-55.5%
Aug 30, 2021	Gadicke Ansbert85	Director, 10% Owner	Sell	50,489	$29.24	$1,476,135.07	-0.3%	-40.5%	-57.2%
Aug 30, 2021	Ubs Oncology Impact Fund L.P.89	10% Owner	Sell	44,358	$29.24	$1,296,884.43	-0.3%	-40.5%	-57.2%
Aug 25, 2021	Ubs Oncology Impact Fund L.P.89	10% Owner	Sell	105,894	$29.29	$3,101,344.22	-0.4%	-28.9%	-49.8%

← PrevPage 10Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC